Logo image of TNG.PA

TRANSGENE SA (TNG.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:TNG - FR0005175080 - Common Stock

0.939 EUR
-0.04 (-4.18%)
Last: 12/29/2025, 10:29:53 AM
Fundamental Rating

1

Overall TNG gets a fundamental rating of 1 out of 10. We evaluated TNG against 81 industry peers in the Biotechnology industry. TNG may be in some trouble as it scores bad on both profitability and health. TNG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TNG had negative earnings in the past year.
TNG had a negative operating cash flow in the past year.
TNG had negative earnings in each of the past 5 years.
TNG had a negative operating cash flow in each of the past 5 years.
TNG.PA Yearly Net Income VS EBIT VS OCF VS FCFTNG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -82.88%, TNG is not doing good in the industry: 71.60% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -82.88%
ROE N/A
ROIC N/A
ROA(3y)-59.77%
ROA(5y)-43.73%
ROE(3y)-151.05%
ROE(5y)-103.3%
ROIC(3y)N/A
ROIC(5y)N/A
TNG.PA Yearly ROA, ROE, ROICTNG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TNG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNG.PA Yearly Profit, Operating, Gross MarginsTNG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

TNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNG has been increased compared to 1 year ago.
TNG has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TNG has been reduced compared to a year ago.
TNG.PA Yearly Shares OutstandingTNG.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TNG.PA Yearly Total Debt VS Total AssetsTNG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -1.64, we must say that TNG is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.64, TNG is doing worse than 61.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.64
ROIC/WACCN/A
WACC7.87%
TNG.PA Yearly LT Debt VS Equity VS FCFTNG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

TNG has a Current Ratio of 0.54. This is a bad value and indicates that TNG is not financially healthy enough and could expect problems in meeting its short term obligations.
TNG has a worse Current ratio (0.54) than 83.95% of its industry peers.
A Quick Ratio of 0.54 indicates that TNG may have some problems paying its short term obligations.
TNG's Quick ratio of 0.54 is on the low side compared to the rest of the industry. TNG is outperformed by 82.72% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.54
TNG.PA Yearly Current Assets VS Current LiabilitesTNG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

TNG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.17%.
Looking at the last year, TNG shows a very negative growth in Revenue. The Revenue has decreased by -20.34% in the last year.
The Revenue for TNG have been decreasing by -14.48% on average. This is quite bad
EPS 1Y (TTM)-31.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.84%
Revenue 1Y (TTM)-20.34%
Revenue growth 3Y-29.03%
Revenue growth 5Y-14.48%
Sales Q2Q%36.11%

3.2 Future

Based on estimates for the next years, TNG will show a decrease in Earnings Per Share. The EPS will decrease by -2.11% on average per year.
TNG is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 30.48% yearly.
EPS Next Y55.56%
EPS Next 2Y21.72%
EPS Next 3Y8.51%
EPS Next 5Y-2.11%
Revenue Next Year4.56%
Revenue Next 2Y7.16%
Revenue Next 3Y12.55%
Revenue Next 5Y30.48%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TNG.PA Yearly Revenue VS EstimatesTNG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M 50M
TNG.PA Yearly EPS VS EstimatesTNG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TNG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TNG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNG.PA Price Earnings VS Forward Price EarningsTNG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNG.PA Per share dataTNG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.72%
EPS Next 3Y8.51%

More info and screens

0

5. Dividend

5.1 Amount

TNG does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TRANSGENE SA

EPA:TNG (12/29/2025, 10:29:53 AM)

0.939

-0.04 (-4.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04
Earnings (Next)03-25 2026-03-25/amc
Inst Owners0.68%
Inst Owner ChangeN/A
Ins Owners0.5%
Ins Owner ChangeN/A
Market Cap257.46M
Revenue(TTM)6.08M
Net Income(TTM)-33.97M
Analysts82.86
Price Target1.5 (59.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.98%
PT rev (3m)-13.72%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)59.32%
EPS NY rev (3m)-271.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)52.77%
Revenue NY rev (3m)30.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 42.34
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.02
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.88%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.77%
ROA(5y)-43.73%
ROE(3y)-151.05%
ROE(5y)-103.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100.08%
Cap/Sales 22.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.54
Altman-Z -1.64
F-Score2
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)165.93%
Cap/Depr(5y)113.96%
Cap/Sales(3y)33.44%
Cap/Sales(5y)22.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.84%
EPS Next Y55.56%
EPS Next 2Y21.72%
EPS Next 3Y8.51%
EPS Next 5Y-2.11%
Revenue 1Y (TTM)-20.34%
Revenue growth 3Y-29.03%
Revenue growth 5Y-14.48%
Sales Q2Q%36.11%
Revenue Next Year4.56%
Revenue Next 2Y7.16%
Revenue Next 3Y12.55%
Revenue Next 5Y30.48%
EBIT growth 1Y-18.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.42%
EBIT Next 3Y-22.93%
EBIT Next 5YN/A
FCF growth 1Y30.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.37%
OCF growth 3YN/A
OCF growth 5YN/A

TRANSGENE SA / TNG.PA FAQ

What is the ChartMill fundamental rating of TRANSGENE SA (TNG.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to TNG.PA.


What is the valuation status for TNG stock?

ChartMill assigns a valuation rating of 0 / 10 to TRANSGENE SA (TNG.PA). This can be considered as Overvalued.


Can you provide the profitability details for TRANSGENE SA?

TRANSGENE SA (TNG.PA) has a profitability rating of 0 / 10.


How financially healthy is TRANSGENE SA?

The financial health rating of TRANSGENE SA (TNG.PA) is 0 / 10.